Paper39240337
Therapeutic drug monitoring in tuberculosis.
Sarkar M and 1 other. Eur J Clin Pharmacol, 2024. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Therapeutic drug monitoring in tuberculosis. Papers, record 39240337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39240337
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Monitoring | Major topic |
| Antitubercular Agents | Major topic |
| Tuberculosis | Major topic |
| Humans | |
| Drug Interactions | |
| Tuberculosis, Multidrug-Resistant | |
| HIV Infections |
Source PubMed
References166
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25809764 | Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. | Int J Infect Dis | 2015 | https://conductscience.org/library/papers/25809764 | PubMed |
| 2 | 31729908 | Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. | Am J Respir Crit Care Med | 2019 | https://conductscience.org/library/papers/31729908 | PubMed |
| 3 | 30496457 | Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis. | Clin Infect Dis | 2018 | https://conductscience.org/library/papers/30496457 | PubMed |
| 4 | 3778104 | [Permanent malabsorption of rifampicin in a diabetic with celiac disease]. | Arch Fr Pediatr | 1986 | https://conductscience.org/library/papers/3778104 | PubMed |
| 5 | 20498324 | Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. | Antimicrob Agents Chemother | 2010 | https://conductscience.org/library/papers/20498324 | PubMed |
| 6 | 32747933 | Clofazimine pharmacokinetics in patients with TB: dosing implications. | J Antimicrob Chemother | 2020 | https://conductscience.org/library/papers/32747933 | PubMed |
| 7 | 26828056 | End TB with precision treatment! | Eur Respir J | 2016 | https://conductscience.org/library/papers/26828056 | PubMed |
| 8 | 21834763 | Dried blood spots: a new tool for tuberculosis treatment optimization. | Curr Pharm Des | 2011 | https://conductscience.org/library/papers/21834763 | PubMed |
| 9 | 38708036 | Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis. | J Clin Tuberc Other Mycobact Dis | 2024 | https://conductscience.org/library/papers/38708036 | PubMed |
| 10 | 16028152 | Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. | Clin Infect Dis | 2005 | https://conductscience.org/library/papers/16028152 | PubMed |
| 11 | 29735562 | Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29735562 | PubMed |
| 12 | 29701775 | Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. | J Antimicrob Chemother | 2018 | https://conductscience.org/library/papers/29701775 | PubMed |
| 13 | 33684562 | Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. | Int J Infect Dis | 2021 | https://conductscience.org/library/papers/33684562 | PubMed |
| 14 | 25678771 | Profile of delamanid for the treatment of multidrug-resistant tuberculosis. | Drug Des Devel Ther | 2015 | https://conductscience.org/library/papers/25678771 | PubMed |
| 15 | 8371737 | Malabsorption of antimycobacterial medications. | N Engl J Med | 1993 | https://conductscience.org/library/papers/8371737 | PubMed |
| 16 | 25676682 | Safety and tolerability profile of second-line anti-tuberculosis medications. | Drug Saf | 2015 | https://conductscience.org/library/papers/25676682 | PubMed |
| 17 | 24349775 | Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA. | Tuberc Res Treat | 2013 | https://conductscience.org/library/papers/24349775 | PubMed |
| 18 | 28584143 | Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28584143 | PubMed |
| 19 | 21310881 | Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. | Eur Respir J | 2011 | https://conductscience.org/library/papers/21310881 | PubMed |
| 20 | 25861340 | Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. | Tuberc Respir Dis (Seoul) | 2015 | https://conductscience.org/library/papers/25861340 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42010496 | Towards precision dosing of contezolid: moderate hepatic impairment increases plasma concentration of contezolid in anti-tuberculosis treatment. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/42010496 | PubMed |
| 41605541 | Host- and pathogen-related determinants of pulmonary versus extrapulmonary tuberculosis. | Eur Respir Rev | 2026 | https://conductscience.org/library/papers/41605541 | PubMed |
| 41566098 | Therapeutic Drug Monitoring for Improving Tuberculosis Treatment Outcomes: A Scoping Review of Clinical Studies. | Clin Pharmacokinet | 2026 | https://conductscience.org/library/papers/41566098 | PubMed |
| 41254567 | Construction and clinical application of an innovative pharmacist-led service model for therapeutic drug monitoring in tuberculosis treatment: a pragmatic randomized controlled trial. | BMC Pulm Med | 2025 | https://conductscience.org/library/papers/41254567 | PubMed |
| 41204126 | Global burden of HIV and drug-resistant tuberculosis co-infection and its attributable risk factors, 1990 to 2021, with projections to 2031. | BMC Infect Dis | 2025 | https://conductscience.org/library/papers/41204126 | PubMed |
| 40698037 | Extensive, Multifocal Pott Disease in a United States-Born Veteran Without Human Immunodeficiency Virus. | Open Forum Infect Dis | 2025 | https://conductscience.org/library/papers/40698037 | PubMed |
| 39841361 | Tuberculosis vaccines and therapeutic drug: challenges and future directions. | Mol Biomed | 2025 | https://conductscience.org/library/papers/39841361 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39240337
GET https://conductscience.org/api/papers/v1/39240337/references?page=2